Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.41 |
| ▸ | TYMP | P19971 | 1/20 | 0.35 |
| ▸ | TK1 | P04183 | 5/20 | 0.35 |
| ▸ | TK2 | O00142 | 2/20 | 0.35 |
| ▸ | TYMS | P04818 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3290516 | 0.86 | RNASE1 (0.43) | RNASE1TYMPTK1TK2TYMS | |
| SCHEMBL6735596 | 0.85 | RNASE1 (0.40) | RNASE1TYMPTK1TK2TYMS | |
| SCHEMBL6232615 | 0.85 | RNASE1 (0.42) | RNASE1TYMPTK1TK2TYMS | |
| SCHEMBL6324546 | 0.84 | RNASE1 (0.45) | RNASE1TYMPTK1TK2TYMS | |
| SCHEMBL8027668 | 0.82 | RNASE1 (0.41) | RNASE1TK1TK2TYMS | |
| SCHEMBL8034055 | 0.81 | RNASE1 (0.40) | RNASE1TYMPTK1TK2TYMS | |
| SCHEMBL2379935 | 0.80 | RNASE1 (0.56) | RNASE1TYMPTK1TK2TYMS | |
| SCHEMBL5531136 | 0.80 | RNASE1 (0.56) | RNASE1TYMPTK1TK2TYMS | |
| SCHEMBL5531135 | 0.80 | RNASE1 (0.56) | RNASE1TYMPTK1TK2TYMS | |
| SCHEMBL8027766 | 0.80 | RNASE1 (0.41) | RNASE1TYMPTK1TK2TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6677471-B2 | USED FOR PREPARATION OF OLIGOMERIC COMPOUNDS HAVING PHOSPHITE, PHOSPHODIESTER, PHOSPHOROTHIOATE, PHOSPHORODITHIOATE OR OTHER LINKAGES | ISIS PHARMACEUTICALS, INC. | 2004-01-13 | — | — | US | disclosed |
| US-20030149260-A1 | Process for the synthesis of oligomeric compounds | ISIS PHARMACEUTICALS, INC. | 2003-08-07 | — | — | US | disclosed |
| US-6521775-B2 | Genetically engineered oligonucleotides for use as diagnostic and therapeutic tools in gene therapy | ISIS PHARMACEUTICALS, INC. | 2003-02-18 | — | — | US | disclosed |
| US-6399756-B1 | OLIGONUCLEOTIDE | ISIS PHARMACEUTICALS, INC. | 2002-06-04 | — | — | US | disclosed |
| US-20020055623-A1 | Process for the synthesis of oligomeric compounds | ISIS PHARMACEUTICALS. INC. | 2002-05-09 | — | — | US | disclosed |
| US-6326478-B1 | OLIGONUCLEOTIDES AND MEDICAL DIAGNOSIS, METABOLISM | ISIS PHARMACEUTICALS, INC. | 2001-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055623-A1 | Process for the synthesis of oligomeric compounds | PPIP5K2, FDPS, GGPS1 | RNASE1 1668/4885TYMP 44/4885TK1 125/4885 |
| US-20030149260-A1 | Process for the synthesis of oligomeric compounds | PPIP5K2, FDPS, GGPS1 | RNASE1 1668/4885TYMP 44/4885TK1 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.